EXCLUSIVE ONLINE CONTENT
On November 20 at the 6th Annual Personalized Nanomedicine Symposium, researchers working with Excision BioTherapeutics, a gene therapy company focusing on curing viral infectious diseases, delivered two oral presentations to review the multiple years of…
Protalix BioTherapeutics, Inc. and its development and commercialization partner, Chiesi Farmaceutici S.p.A. recently announced that they have completed a successful Type B Pre-Biologics License Application (BLA) meeting with the US FDA regarding….
Flexion Therapeutics, Inc. recently announced clearance of the company’s Investigational New Drug (IND) application for FX201 in knee osteoarthritis.
This new global nanotechnology association will bolster the necessary links between research and industries and facilitate the adoption and commercialization of…….
Crown Bioscience recently announced the launch of a new tumor organoid drug development platform with the potential to significantly improve the……